How Low Can AbbVie Stock Really Go?
AbbVie (ABBV) faces a recent stock dip amid broader market gains, yet its immunology engine and robust dividend outlook signal long-term strength. But as investors weigh near-term market shifts, it’s worth asking: can ABBV navigate cyclical pressures and maintain its growth trajectory?
Before judging its downturn reslience, let’s look at where AbbVie stands today.
- Size: AbbVie is a $389 Bil company with $60 Bil in revenue currently trading at $220.18.
- Fundamentals: Last 12 month revenue growth of 7.4% and operating margin of 24.1%.
- Liquidity: Has Debt to Equity ratio of 0.18 and Cash to Assets ratio of 0.04
- Valuation: AbbVie stock is currently trading at P/E multiple of 163.1 and P/EBIT multiple of 85.8
- Has one instance since 2010 where it dipped >30% in < 30 days and subsequently returned 71.2% within a year. See ABBV Dip Buy Analysis.
These metrics point to a Moderate operational performance, alongside Moderate valuation – making the stock Fairly Priced. For details, see Buy or Sell ABBV Stock
That brings us to the key consideration for investors looking to add ABBV to their portfolio: how resilient is ABBV stock if markets turn south? This is where our downturn resilience framework comes in. Suppose ABBV stock falls 20-30% to $154 – can investors comfortably hold on? Turns out, the stock has fared worse than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. Below, we dive deeper into each such downturn.
2022 Inflation Shock
- ABBV stock fell 23.3% from a high of $174.96 on 8 April 2022 to $134.21 on 30 September 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 7 February 2024
- Since then, the stock increased to a high of $244.38 on 1 October 2025 , and currently trades at $220.18
| ABBV | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -23.3% | -25.4% |
| Time to Full Recovery | 495 days | 464 days |
2020 Covid Pandemic
- ABBV stock fell 34.0% from a high of $97.79 on 12 February 2020 to $64.50 on 23 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 30 June 2020
| ABBV | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -34.0% | -33.9% |
| Time to Full Recovery | 99 days | 148 days |
2018 Correction
- ABBV stock fell 48.9% from a high of $123.21 on 26 January 2018 to $62.98 on 15 August 2019 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 9 December 2021
| ABBV | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -48.9% | -19.8% |
| Time to Full Recovery | 847 days | 120 days |
Feeling jittery about ABBV stock? Consider portfolio approach.
A Multi Asset Portfolio Beats Picking Stocks Alone
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices